Certara, Inc. (NASDAQ:CERT - Get Free Report) insider Patrick F. Smith sold 14,427 shares of the company's stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total transaction of $243,094.95. Following the completion of the transaction, the insider now owns 50,091 shares of the company's stock, valued at $844,033.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Certara Trading Up 5.2 %
Shares of CERT stock opened at $17.75 on Friday. Certara, Inc. has a 1-year low of $11.81 and a 1-year high of $24.96. The company has a quick ratio of 2.62, a current ratio of 2.62 and a debt-to-equity ratio of 0.28. The stock's 50-day moving average is $17.60 and its 200 day moving average is $15.90.
Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Thursday, February 29th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.04). The company had revenue of $88.01 million for the quarter, compared to analyst estimates of $86.80 million. Certara had a negative net margin of 15.62% and a positive return on equity of 4.33%. As a group, equities analysts anticipate that Certara, Inc. will post 0.29 EPS for the current fiscal year.
Hedge Funds Weigh In On Certara
The Gold Grab of the Century
From Colonial Metals | Ad
When central banks buy gold…
The rich buy right along with them.
And central banks are buying at breakneck pace.
Last year… 1,037 tons.
Just 45 tons less than the record set two years ago.
That's why we have released our Free Precious Metals Investment Guide.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Raymond James & Associates raised its position in shares of Certara by 83.4% in the first quarter. Raymond James & Associates now owns 37,080 shares of the company's stock worth $796,000 after acquiring an additional 16,861 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Certara by 1.1% in the first quarter. Bank of New York Mellon Corp now owns 384,913 shares of the company's stock worth $8,268,000 after buying an additional 4,107 shares in the last quarter. HighTower Advisors LLC raised its stake in Certara by 71.6% during the first quarter. HighTower Advisors LLC now owns 19,847 shares of the company's stock worth $440,000 after purchasing an additional 8,282 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Certara by 18.3% in the first quarter. PNC Financial Services Group Inc. now owns 5,841 shares of the company's stock valued at $126,000 after acquiring an additional 905 shares during the last quarter. Finally, MetLife Investment Management LLC acquired a new position in shares of Certara in the 1st quarter valued at $111,000. Institutional investors and hedge funds own 73.96% of the company's stock.
Analyst Ratings Changes
CERT has been the topic of several research reports. SVB Leerink initiated coverage on shares of Certara in a research note on Monday, February 26th. They set a "market perform" rating and a $19.00 price target on the stock. Leerink Partnrs reissued a "market perform" rating on shares of Certara in a research note on Monday, February 26th. UBS Group raised their price objective on shares of Certara from $17.00 to $20.00 and gave the company a "neutral" rating in a research note on Friday, March 1st. Barclays boosted their price target on Certara from $16.00 to $18.00 and gave the stock an "equal weight" rating in a research note on Thursday, January 25th. Finally, Jefferies Financial Group increased their price objective on Certara from $14.00 to $15.50 and gave the company a "hold" rating in a research report on Friday, March 1st. Eight research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $19.64.
View Our Latest Stock Report on Certara
About Certara
(
Get Free Report)
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
